I think that was a status update as of yesterday. Like I said, info seems to be in short supply here, but one news source says that Hospira can sell their versions of MDCO's drug. Judge wasn't Sparks.
Been digging through the filings for almost an hour. Found out that the Columbian operations had revs of about $3.3 million, which were backed out of the $8.029 million total. Therefore it looks like Q 4 revs were in the area of $2.8 million. If they averaged about $80 per barrel (figuring some NG, NGLs, but mostly oil) it would appear that Q 4 production was about 35,000 BOE or about 45% of the year's total production.
I couldn't find a breakout anywhere of Q 4 numbers, could anyone else???
Also some of the interest costs were deferred and therefore non cash expenses......can't remember exact number but was between $1 - 2 million.
Down a few cents on low volume. Just catching its breath so it can go on a nice run the rest of the week. Trading at 1/2 of book value and 1.5 X cash flow. Somebody will come knocking on the door soon.
I believe I got the initial mention about SJNK from this msg board, probably from you. Thank you for that. Been watching it for several weeks, finally decided to put some cash to work.
As of Friday's close I was up to about 70% cash. Can really find any regular stocks to buy at these levels, so I went for SJNK. Yield isn't all that much less than many leveraged junk bond CEFs.
Is an ETF that holds shorter term junk bonds. Yields 5% annual, pays monthly, and x-date should be about April 3rd. I threw about 25% of my big cash position in here to get some yield. I consider it almost like a Money Market fund in the short term anyway. Trades very smoothly......1 cent spread.
Concern.......Debt of $20 million and the cost of that debt of $4.5 million. That's about a 25% interest rate (was their origination fees?) as not all of that $20 mil wasn't outstanding for the full year. Can't borrow anymore for the size of this company. Might be able to "grow into" this amount of debt, but probably need some equity offerings to achieve the needed growth. Inevitable in my opinion.
Revenues.....just some questions here. Full year revenue was actually less than 9 month revenue. Was this because of the Columbia unit sale? I know they quit booking sales from there as of Oct. 1st, but did they "back out" sales generated earlier in the year?
9 month revenues were $8.478 million
Full year revenues were $8.029 million
Thanks to anyone who can address these concerns.
Over the last few years I've wittled my position from 1000s of shares down to just hundreds.. Just turned age 62 and can't handle the BIG gambles any longer. Been here in varying amounts since a few months after approval. Optimistic but cautious.
We have a family function every year. Two of my sisters (age 63 and 64) and myself were all born in a 5 day span one year apart each. Throw in a few other BDs around that time and we have quite a get-together every year.
Thanks to all for BD wishes.............Kel
J.........I picked up some T at 32.30 not long ago in my "non trading" regular account. Will continue to hold. This is an account where I don't want any trading gains so as not to endanger my OBAMACARE subsidy of over $400 per month. Just have to manage and control my reportable income. Other trading is in my IRA where gains are great and acceptable.
Provenge (DNDN) was approved by the FDA at a one time treatment cost of almost $100,000and it prolonged life by a few months.
Yes, was March 22..........Thanks very much. Four boomers in my family now in their 60s. Who's going to pay for all that Social Security? Me @ 62 and my 3 sisters @ 63, 64, and 68. Thank the Lord for our good (relatively) health.
Look at NEPT.....making krill oil in Canada with fish from the Antarctic. Not a holder, was just looking at it.
Kel.........former holder of AMRN
Who'd want to assume that pension liability? AKS will do well (perhaps great) when times are good for the steel industry, but will be the ugly duckling when times are difficult.
Right on. Less than 1/2 of independently evaluated book value and about 1.5 X cash flow. We don't need Hal's exaggerations for SFY to be a great value. It already is.
Sold it for a .19 loss. Wasn't tracking well or acting well. Sold it early in the day which was a good thing. Much lower now than the 56.29 I sold it at.